KP-1461

KP-1461
Clinical data
Drug class	Reverse transcriptase inhibitor
Legal status
Legal status	Investigational;
Identifiers
CAS Number	815588-85-3;
PubChem CID	51003457;
DrugBank	05644;
ChemSpider	32702166;
UNII	3PEN569TJP;
CompTox Dashboard (EPA)	DTXSID101112194 ;
Chemical and physical data
Formula	C16H23N4O6
Molar mass	367.382 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCCCOC(=O)NC1=NCN(C(=O)N1)[C@H]2C[C@@H]([C@H](O2)CO)O;
	InChI InChI=1S/C16H28N4O6/c1-2-3-4-5-6-7-25-16(24)19-14-17-10-20(15(23)18-14)13-8-11(22)12(9-21)26-13/h11-13,21-22H,2-10H2,1H3,(H2,17,18,19,23,24)/t11-,12+,13+/m0/s1; Key:SZWIAFVYPPMZML-YNEHKIRRSA-N;

KP-161 is an experimental antiviral drug being studied for the treatment of HIV/AIDS.^[1] It belongs to the class of nucleoside reverse transcriptase inhibitors.^[2]

KP-1461 is a prodrug of the active antiviral agent KP-1212.^[3]

References

^ "KP-1461". AIDSinfo. U.S. Department of Health and Human Services. Archived from the original on 2019-08-11. Retrieved 2018-09-04.
^ Harris K, Sergueev D, Reno J (December 2006). "The chemistry and biology of KP-1461, a selective nucleoside mutagen for HIV therapy". Retrovirology. 3 (Suppl 1) S13. doi:10.1186/1742-4690-3-S1-S13. PMC 1716920.
^ "KP-1461". DrugBank. Canadian Institutes of Health Research.